DOI: https://doi.org/10.22141/2224-0721.14.6.2018.146073

Peculiarities of Styfimol impact on carbohydrate, lipid metabolism and blood adipokine levels in patients with type 2 diabetes with obesity and arterial hypertension

K.O. Zuiev, I.M. Khanko

Abstract


Background. The purpose of the study was to eva­luate the impact of treatment with a fixed combination of the extract of garcinia cambogia 0.1 g (equivalent to hydroxycitric acid 0.05 g), chromium picolinate 0.0001 g, L­tyrosine 0.5 g, L­carnitine 0.015 g, dried brown algae extract (Fucus vesiculosus L.) equivalent to iodine 0.037 mg on lipid and carbohydrate metabolism, as well as on the level of adipokines (leptin and adiponectin) in the blood of type 2 diabetes patients with obesity and arterial hypertension. Materials and methods. The study included 53 patients (of whom 25 were men) aged 55.90 ± 2.15 years with type 2 diabetes, hypertension and obesity (body mass index ≥ 30 kg/m2). Results. In the main group (n = 30), after 12 weeks of treatment with such a fixed combination of 1 capsule 3 times daily, the HbA1c level decreased by 0.87 ± 0.14 % (P1 = 0.0001), in the control group (n = 23) — by 0.17 ± 0.16 % (P1 = 0.1), the difference between the main and control groups was statistically significant (P2 = 0.001). The level of fasting plasma glucose in the main group reduced by 8.00 ± 4.26 % (P1 = 0.03), in the control group — by 2.7 ± 4.8 % (P1 = 0.2), the difference between the groups was statistically non­significant (P2 = 0.4). The level of low­density lipoproteins in the main group decreased by 18.20 ± 5.43 % (P1 = 0.001), in the control group — increased by 6.9 ± 6.2 % (P1 = 0.7), the difference between the groups was statistically significant (P2 = 0.003). In the main group, there was a reduction in triglyceride levels by 14.9 ± 6.5 % (P1 = 0.02), in the control group — an increase by 20.30 ± 7.46 % (P1 = 0.04), the difference between the groups was statistically significant (P2 = 0.008). In the main group, the level of high­density lipoproteins increased by 20.2 ± 6.8 % (P1 = 0.03), in the control group — decreased by 3.7 ± 7.7 % (P1 = 0.12), the difference between the groups was statistically significant (P2 = 0.02). Therapy with the study drug did not affect insulin resistance, which was determined by the НOMA­IR, and the level of plasma fasting insulin. Therapy with the study drug showed a decrease in leptin levels by 21.4 ± 6.1 % (P1 = 0.004), and a tendency to increase in adiponectin levels by 19.30 ± 9.36 % (P1 = 0.39). Conclusions. The reduction in body weight on the background of study drug therapy led to an improvement in carbohydrate and lipid metabolism, and also had a positive effect on leptin levels in the blood plasma.


Keywords


obesity; type 2 diabetes; lipids; garcinia cambogia; L-carnitine; chromium picolinate; leptin; adiponectin

References


Lindström J, Ilanne-Parikka P. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: The follow-up results of the Finnish Diabetes Prevention Study. Lancet. 2006 Nov 11;368(9548):1673-9. doi: 10.1016/S0140-6736(06)69701-8.

Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.

UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism. 1990 Sep;39(9):905-12.

Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992 Jun;16(6):397-415.

Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002 Mar;25(3):608-13.

Wadden TA, Bantle JP, Blackburn GL, et al; Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring). 2014 Jan;22(1):5-13. doi: 10.1002/oby.20662.

Zuiev KO. Peculiarities of bariatric impact of Styfimol in patients with type 2 diabetes with obesity and hypertension. Mìžnarodnij endokrinologìčnij žurnal. 2017;13(8):596-603. doi: 10.22141/2224-0721.13.8.2017.119277. (in Ukrainian).

Zuiev KO. Features of influence of combination of garcinia cambogia, chromium picolinate, L-tyrosine, L-carnitine, Fucus vesiculosus L. on lipid and carbohydrate metabolism, as well as on the level of adipokines (leptin and adiponectin) in blood in patients with diabetes type 2 with obesity and arterial hypertension. In: Proceedings of the Conference «Pressing Issues of Clinical Endocrinology, Immunology and Allergology» (Chernivtsi, October 24–25, 2013). Mìžnarodnij endokrinologìčnij žurnal. 2013;(54):141-142. (in Ukrainian).

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.

Ishirara K, Oyaizu S, Onuki K, Lim K, Fushiki T. Chronic (-)-hydroxycitrate administration spares carbohydrate utilization and promotes lipid oxidation during exercise in mice. J Nutr. 2000 Dec;130(12):2990-5. doi: 10.1093/jn/130.12.2990.

Hayamizu K, Hirakawa H, Oikawa D, et al. Effect of Garcinia cambogia extract on serum leptin and insulin in mice. Fitoterapia. 2003 Apr;74(3):267-73.

Kim KY, Lee HN, Kim YJ, Park T. Garcinia cambogia extract ameliorates visceral adiposity in C57BL/6J mice fed on a high-fat diet. Biosci Biotechnol Biochem. 2008 Jul;72(7):1772-80. doi: 10.1271/bbb.80072.

Kim JE, Jeon SM, Park KH, et al. Does Glycine max leaves or Garcinia Cambogia promote weight-loss or lower plasma cholesterol in overweight individuals a randomized control trial. Nutr J. 2011 Sep 21;10:94. doi: 10.1186/1475-2891-10-94.

Vasques CA, Rossetto S, Halmenschlager G, et al. Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity. Phytother Res. 2008 Sep;22(9):1135-40. doi: 10.1002/ptr.2323.

Sergiyenko OO, Sergiyenko VO, Pidsadochna II, et al. Efficiency of Styfimol in treatment of obesity. In: Karachentsev YuI, editor. Fundamental'na ta klinichna endokrynologija: problemy, zdobutky, perspektyvy [Fundamental and clinical endocrinology: problems, achievements, perspectives]. Kharkiv: KMAPE; 2009. 146 p. (in Ukrainian).

Sala M, Breithaupt L, Bulik CM, Hamer RM, La Via MC, Brownley KA. A Double-Blind, Randomized Pilot Trial of Chromium Picolinate for Overweight Individuals with Binge-Eating Disorder: Effects on Glucose Regulation. J Diet Suppl. 2017 Mar 4;14(2):191-199. doi: 10.1080/19390211.2016.1207124.

Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther. 2003 May;25(5):1429-39.

Serban MC, Sahebkar A, Mikhailidis DP, et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016 Jan 12;6:19188. doi: 10.1038/srep19188.

Nazary-Vannani A, Ghaedi E, Mousavi SM, Teymouri A, Rahmani J, Varkaneh HK. The effect of L-carnitine supplementation on serum leptin concentrations: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018 Jun;60(3):386-394. doi: 10.1007/s12020-018-1559-7.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта